Asamoah, Esmelinda

Asamoah, Esmelinda was paid $179K by Medicaid between May 2023 and Dec 2024, across 5 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 43% of everything it billed.

33Billing provider infoASAMOAH, ESMELINDA
WORCESTER, MA 01602

33aNPI1073213674assigned 03/03/2023

33bProvider typeFamily Nurse Practitioner

28Total paid$179K

24GClaims2,908

24DCodes billed5

24AFirst – last monthMay 2023 – Dec 2024

Compared with peers

Next to other Family Nurse Practitioner providers in Massachusetts

Rank by total paid#22 of 327

Median peer was paid$5K

This provider vs. median34×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2023	1,352	$78K
2024incomplete	1,556	$101K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	43%	913	645	$77K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	38%	1,475	973	$69K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	17%	463	402	$31K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.4%	44	42	$3K
81025		<1%	13	13	$92.80

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.